The ability of celecoxib to inhibit the COX-2 enzyme with subsequent decreased PGE2, which plays a crucial role in the generation of VEGF, may be the cause of the suppression of angiogenesis translated by decreased VEGF levels by the concurrent use of celecoxib with FOLFIRI [23]. When compared to sporadic forms, COX inhibition has shown statistically significant results in lowering the risk of familial CRC [4]. This evidence concerns the gene PTGS2 and colorectal carcinoma.